Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers

REFERENCES

• Zeuzem S, Feinman SV, Rasenack J, Heathcote J, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450.
   PubMed Web of Science ®Google Scholar
• Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81–85.
   PubMed Web of Science ®Google Scholar
• Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.
   PubMed Web of Science ®Google Scholar
• Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther. 2006;24: 585–591.
   PubMed Web of Science ®Google Scholar
• Fultz SL, Justice AC, Butt AA, Rabeneck L, Rodriguez-Barradas MC, Weissman S. Testing, referral, and treatment patterns for hepatitis C coinfection in a cohort of veterans with HIV infection. Clin Infect Dis. 2003;36:1039–1046.
   PubMed Web of Science ®Google Scholar
• Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showier G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141–147.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Ha!fon P, Rosenthal E, Pialoux G, Benhamou Y, Perronne C, Pol S. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": Modifications in two large surveys between 2004 and 2006. J HepatoL 2008;48:35–42.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Rosenthal E, Ha!fon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immuno-deficiency virus coinfection: From large trials to real life. J Viral Hepat. 2006;13:678–682.
   PubMed Web of Science ®Google Scholar
• Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepa-titis C treatment in HIV-infected homeless and marginally housed persons. AIDS. 2005;19(Suppl 3):S208–214.
   PubMed Web of Science ®Google Scholar
• Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754–758.
   PubMed Web of Science ®Google Scholar
• Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral ther-apy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J GastroenteroL 2005;100:1772–1779.
   PubMed Web of Science ®Google Scholar
• Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39: 999–1007.
   PubMed Web of Science ®Google Scholar
• Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: Recommenda-tions from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepa-titis C Program office. Am J GastroenteroL 2006;101: 2360–2378.
   PubMed Web of Science ®Google Scholar
• Management of Hepatitis C: 2002. National Institutes of Health Consensus Conference Statement. 2002;19:1-46. Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
   Google Scholar
• APASL Hepatitis C Working Party. Asian Pacific Associa-tion for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol HepatoL 2007;22:615–633.
   PubMed Web of Science ®Google Scholar
• Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890–896.
   PubMed Web of Science ®Google Scholar
• Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908–914.
   PubMed Web of Science ®Google Scholar
• Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindica-tions in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005;19(Suppl 3):S99–S105.
   PubMed Web of Science ®Google Scholar
• Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18(Suppl 1):S49–59.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Zhou Y, Dana D, Fichtenbaum CJ, Butt Al, Andersen J, et al. High frequency of anemia in HCV-HIV coinfected persons receiving weight based ribavirin and zidovudine. Presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–15, 2005; San Francisco, CA.
   Google Scholar
• Butt AA, Herrine S. Hepatitis C. In: Yu VL, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccines. 2nd ed. New York: Apple Tree Productions; 2002.
   Google Scholar
• Butt AA, Singh N. Hepatitis C. Prevention, therapy and role of transplantation. In: Wenzel R, ed. Prevention and Control of Nosocomial Infections. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2003.
   Google Scholar
• Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis. 2000;20:185–199.
   PubMed Web of Science ®Google Scholar
• Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coin-fected subjects: An early report. Gut. 2000;47:694–697.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3. J HepatoL 2004;40:993–999.
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171.
   PubMed Web of Science ®Google Scholar